Tilray Brands Inc. has achieved a groundbreaking regulatory milestone in Italy, securing the first-ever authorization from the Italian Ministry of Health to distribute medical cannabis flower for therapeutic use. This approval allows Tilray Medical, a division of Tilray Brands, to introduce three new varieties of medical cannabis in Italy: Tilray THC 25%, Tilray THC 18%, and Tilray THC 9% / CBD 9%. As the first company in Italy to receive such authorization, Tilray continues to expand its leadership in the European medical cannabis market, which includes operations in Germany, Portugal, Poland, and the United Kingdom. This development represents a significant step in enhancing patient access to high-quality, EU-GMP certified cannabinoid-based therapies across Italy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。